*IKZF1* encodes Ikaros, a zinc-finger transcription factor with a regulatory role in lymphopoiesis and the maintenance of cytokine expression in mature lymphocytes ([@B1],[@B2]). Mice with a null mutation in *IKZF1* (Ikaros^−/−^) display complete penetrance of leukemia, increased CD4^+^ to CD8^+^ T-cell ratios, and defects in T-cell maturation, including decreased T-cell receptor signaling thresholds during central tolerance ([@B1]). Mice heterozygous for the null mutation in *IKZF1* (Ikaros^+/−^) exhibit milder features, but abnormalities including reduced B-cell precursors, a highly increased proliferative response to T-cell receptor engagement, and high rates of T-cell leukemia and lymphomas have been observed ([@B3]).

Human studies suggest a specific role for Ikaros in childhood acute lymphoblastic leukemia (C-ALL). Development of C-ALL is linked to somatically acquired mutations that add to inherited cancer susceptibility alleles ([@B4]). In 2009, deletions of *IKZF1* were reported in 28.6% of C-ALL affected adults ([@B5]) and in 83.7% of *BCR-ABL1* C-ALL patients examined ([@B6]). Combined, the human and murine studies suggest that diminished expression of *IKZF1* interrupts lymphocyte development, creating conditions that maintain the rapidly dividing lymphoblasts that characterize ALL.

Two recent genome-wide association (GWA) studies have identified a C-ALL susceptibility locus near *IKZF1* ([@B7],[@B8]). The identified C-ALL-associated single nucleotide polymorphisms (SNPs), rs4132601 (T\>G) and rs11978267 (A\>G), as well as two others near *IKZF1*, rs11980379 (T\>C) and rs10272724 (T\>C), showed evidence of association with type 1 diabetes in a separate GWA study (*P* = 2.0 × 10^−6^, 2.6 × 10^−6^, 2.5 × 10^−6^, and 1.4 × 10^−6^, respectively; [www.t1dbase.org](http://www.t1dbase.org)), although not at the level the authors required for follow-up (*P* \< 1 × 10^−6^) ([@B4]). All four SNPs are in high linkage disequilibrium (LD, *r*^2^\>0.98) in the British 1958 Birth Cohort (B1958) controls (<http://www.b58cgene.sgul.ac.uk>), suggesting they mark the same potential causal variant for type 1 diabetes. Type 1 diabetes is a disease of abnormal immunity, wherein autoimmune destruction of pancreatic β-cells results in a state of insulin dependency ([@B8],[@B9]). Type 1 diabetes results from the influence of environmental factors acting on an underlying genetic susceptibility ([@B9]). Although no direct link between*IKZF1*and type 1 diabetes has been reported, the previously reported, but not highlighted or followed up, association of the chromosome 7p12.2 region containing*IKZF1*with type 1 diabetes ([@B10]; [www.t1dbase.org](http://www.t1dbase.org)), the immunologic importance of*IKZF1* ([@B11]), and the association of*IKZF1*with susceptibility to C-ALL ([@B7],[@B8]) prompted us to select the SNP most associated with type 1 diabetes, rs1027274 (T\>C) (*P* = 1.4 × 10^−6^) near*IKZF1*,for follow-up genotyping to assess association with type 1 diabetes and to determine whether a common genetic component exists for C-ALL and type 1 diabetes.

RESEARCH DESIGN AND METHODS {#s5}
===========================

Samples. {#s6}
--------

A total of 8,333 type 1 diabetes cases, 9,947 controls, and 3,997 families were genotyped at rs10272724 using TaqMan ([Supplementary Methods](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0446/-/DC1)). All samples were of white European ancestry. Cases were diagnosed with type 1 diabetes before 17 years of age (mean age at diagnosis = 7.8 years) and were from the Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory Genetic Resource Investigating Diabetes study (<http://www.childhood-diabetes.org.uk/grid.shtml>). Controls were obtained from the British 1958 Birth Cohort (*n* = 6,899; <http://www.cls.ioe.ac.uk/studies.asp?section=000100020003>) and the WTCCC UK Blood Service (UKBS) sample collection (*n* = 3,048) ([@B10],[@B12]).

Statistical analysis. {#s7}
---------------------

STATA version 10 (StataCorp LP, College Station, TX) was used to perform association analyses (<http://www.stata.com>). rs10272724 was in Hardy-Weinberg equilibrium in unaffected parents and control subjects (*P* \> 0.05). Case-control data were modeled using logistic regression, with disease status as the outcome variable and counts of the minor allele (coded 0, 1, and 2) as the independent variable, assuming a multiplicative allelic effects model. Geographic region was included as a covariate in the model ([Supplementary Methods](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0446/-/DC1)). Families were analyzed using the transmission disequilibrium test ([@B13]) ([Supplementary Methods](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0446/-/DC1)). The interdependency of rs10272724 and rs4948088 in the 7p12 region was examined by stepwise logistic regression.

Peripheral blood mononuclear cell isolation and preparation of DNA and RNA. {#s8}
---------------------------------------------------------------------------

Peripheral blood mononuclear cells (PBMCs) were purified from heparinized blood diluted 1:1 in PBS (without Ca^2+^ and Mg^2+^, GIBCO, Invitrogen, Carlsbad, CA), and 15 mL aliquots were layered onto 10 mL aliquots of Lympholyte (Cedarlane Laboratories Ltd., Burlington, Ontario) followed by centrifugation at 800*g* for 20 min at room temperature. The harvested PBMC layer was washed twice with ice-cold PBS and centrifuged at 300*g* for 10 min at 4°C. Pellets were resuspended in TRIzol (Invitrogen) and stored at −80°C in aliquots of 10 × 10^7^ cells/mL. Total RNA from 1 × 10^7^ PBMCs in TRIzol was prepared using chloroform extraction followed by purification with the RNeasy Mini kit (QIAGEN, Hilden, Germany), according to the manufacturer's instructions. RNA quality was assessed using an Agilent 2100 Bioanalyser, and concentration was evaluated by Nanodrop (Thermo Scientific, Waltham, MA). First strand DNA synthesis was carried out on 1 μg of RNA using Superscript III RT kit and oligo-dT (Invitrogen).

Quantitative PCR evaluation of *IKZF1* expression. {#s9}
--------------------------------------------------

Quantitative (q)PCR primers and probe were designed to two transcripts of *IKZF1*, herein referred to as "Isoform 1" and "Isoform 2" ([Supplementary Methods](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0446/-/DC1)). Probes were labeled with the fluorochrome FAM and quenched using TAMRA. qPCR assays contained 5 μL of 1:10 dilution of oligo-dT primed cDNA, prepared as described above, in 20 μL assays. Cycle threshold (Ct) values were measured using a 7900HT ABI prism (Applied Biosystems, Carlsbad, CA) and analyzed using SDS v2.1 software (ABI). qPCR reactions were run in triplicate, and the ΔCt for the transcript level qPCRs was calculated using the *IKZF1* Isoform 1 or Isoform 2 qPCR Ct value minus the single copy gene β2 microglobulin qPCR Ct value. Expression values were compared via one-way ANOVA using Prism software (GraphPad Software Inc., La Jolla, CA).

mRNA expression of genes near rs10272724. {#s10}
-----------------------------------------

Correlation between rs10272724 and expression in three types of cell lines (primary fibroblasts, Epstein--Barr virus-immortalized lymphoblastoid cell lines, and phytohemagglutinin-stimulated primary T-cells) derived from umbilical cord samples of 75 newborns of Western European origin via the GenCord project was examined in silico ([@B14]) using the publicly available HapMap online GENe Expression VARiation (Genevar) resource (<http://www.sanger.ac.uk/resources/software/genevar/>). Nine probes that passed quality control assessment ([Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0446/-/DC1)) were evaluated for correlation of mRNA expression with rs10272724 genotype by linear regression using the Genevar 2.0.1 Java tool ([@B15]) ([Supplementary Methods](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0446/-/DC1)). A *P \<* 0.0056 significance threshold was used within each cell type based on a Bonferroni correction for testing nine transcripts.

Donors. {#s11}
-------

Blood for qPCR experiments was collected from 88 nondiabetic donors (rs10272724: 44 TT, 33 CT, 11 CC) selected from a pregenotyped bioresource and processed within 4 hours ([www.cambroidgebioresource.org.uk](http://www.cambroidgebioresource.org.uk)).

Study ethics. {#s12}
-------------

All DNA samples were collected with ethical approval from the National Health Service Cambridgeshire Research Ethics Committee. Written consent was obtained from all individuals.

RESULTS {#s13}
=======

The minor allele of rs10272724 (T\>C) near *IKZF1* was protective from type 1 diabetes (odds ratio \[OR\] 0.87 \[95% CI 0.83--0.91\], *P* = 4.8 × 10^−9^; [Table 1](#T1){ref-type="table"}, [Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0446/-/DC1)). No evidence of association of rs10272724 with sex or age-at-diagnosis was obtained (*P \>* 0.1). Some samples overlapped with those used in the previous GWA study for type 1 diabetes ([@B10]). However, in each of the sample sets used by Barrett et al. ([@B10]) and in our unique samples, the effect is in the same direction and the overall significance is increased, suggesting the effect is not solely attributable to the original samples ([Table 1](#T1){ref-type="table"}). The minor allele of rs10272724 was also protective in the families with type 1 diabetes, i.e., under-transmitted to affected offspring ([Table 1](#T1){ref-type="table"}; relative risk 0.87 \[95% CI 0.81--0.93\], *P* = 7.6 × 10^−5^). Combined, these results indicate that the minor allele, C, of rs10272724 at 7p12.2 is convincingly associated with a reduced risk of type 1 diabetes (*P* = 1.1 × 10^−11^). Barrett et al. ([@B10]) reported a replicated association with rs4948088 (C\>A) with type 1 diabetes in the 7p12.1 region, 554 kb downstream of *IKZF1*. However, this SNP, marking a confirmed type 1 diabetes locus (<http://www.t1dbase.org/page/Regions>), is not in LD with rs10272724 in *IKZF1* (D' = 0.02, *r*^2^ = 0.0001), and we found by regression analysis that the two effects were independent as both SNPs improve a model with the other SNP included (*P* \< 5.5 × 10^−5^).

###### 

Association of rs10272724 (T\>C) near *IKZF1* in 8,333 type 1 diabetes cases, 9,947 control subjects, and 3,997 families with type 1 diabetes

  Sample set                                                                                                                               No. cases      No. controls             MAF cases         MAF controls          OR (95% CI)                                        *P*[\*](#t1n1){ref-type="table-fn"}
  ---------------------------------------------------------------------------------------------------------------------------------------- -------------- ------------------------ ----------------- --------------------- -------------------------------------------------- -------------------------------------
  Full case-control set                                                                                                                    8,333          9,947                    0.25              0.28                  0.87 (0.83--0.91)[†](#t1n2){ref-type="table-fn"}   4.8 × 10^−9^
  Analysis of genotypes generated in the current report, within sample sets used by published GWA studies[‡](#t1n3){ref-type="table-fn"}                                                                                                                                      
   Set 1 (T1DGC)                                                                                                                           3,850          3,772                    0.25              0.28                  0.85 (0.79--0.91)[†](#t1n2){ref-type="table-fn"}   1.6 × 10^−5^
   Set 2 (WTCCC)                                                                                                                           1,827          1,507                    0.25              0.28                  0.84 (0.76--0.92)                                  0.0014
   Set 3 (Swafford)                                                                                                                        2,666          4,668                    0.26              0.28                  0.90 (0.83--0.98)                                  0.011
                                                                                                                                           No. families   MAF unaffected parents   No. transmitted   No. not transmitted   RR (95% CI)                                        *P*
  Families with type 1 diabetes                                                                                                            3,997          0.27                     1,423             1,642                 0.87 (0.81--0.93)                                  7.6 × 10^−5^
  Overall                                                                                                                                                                                                                                                                     1.1 × 10^−11^

MAF, minor allele frequency; RR, relative risk.

\*No evidence of deviation from a multiplicative allelic effects model was obtained (*P* = 0.33), so *P* values assuming multiplicative allelic effects are reported.

The overall *P* value was obtained by combining the *P* value from the case-control sets and the family transmission disequilibrium test using Fisher's method for combined probability.

†This OR is subject to winner's curse. ‡Barrett et al. ([@B10]) analyzed three datasets in their GWA study, two of which overlap with the samples in the current study. Barrett et al. used the Illumina 550 K SNP chip to genotype rs10272724 in set 1 (4). Genotypes were 99.6% concordant between the Illumina platform and TaqMan in the 3,850 cases and 3,772 controls genotyped using both technologies. Affymetrix 500 K Mapping Array genotypes for neighboring SNPs were used to impute rs10272724 genotypes in set 2 by Barrett et al. because rs10272724 was not genotyped by Affymetrix. T1DGC, Type 1 Diabetes Genetics Consortium; WTCCC, Wellcome Trust Case-Control Consortium.

The relative abundance of two different sets of *IKZF1* transcripts in mRNA extracted from PBMCs isolated from 88 nondiabetic individuals was assessed using qPCR to determine the association of rs10272724 alleles with gene expression. No evidence of allele-specific expression was obtained (*P \>* 0.1; [Fig](#F1){ref-type="fig"}. [1](#F1){ref-type="fig"}). Others have reported a correlation of rs4132601 with *IKZF1* expression in Epstein--Barr virus-transformed lymphoblastoid cell lines from the HapMap GENEVAR resource (\[[@B8]\]; *P =* 0.0017). However, this is likely to be a false effect. The probe originally used (Illumina ID ILMN_1676575) contains two high-frequency SNPs in its target, rs62447207 (G\>T) and rs62447208 (C\>G) in LD with rs10272724 (*r*^2^ = 0.76), rendering it unreliable, as evidenced by the absent *IKZF1* probe in the latest Genevar data from the study by Dimas et al. ([@B14]). In results from 13 eQTL datasets displayed at <http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/>, there is no reliable evidence for an *IKZF1*-associated eQTL. Next, correlation of rs10272724 genotype and expression of nine transcripts from other genes within 1 Mb of rs10272724 in three types of cell lines was tested using the latest Genevar dataset by Dimas et al. ([@B14]). No correlation was observed between rs10272724 and expression of any of the five neighboring genes (\[[@B14]\], [Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0446/-/DC1)).

![Association of *IKZF1* expression with rs10272724 (T\>C) genotype in 88 unaffected individuals. *A*: qPCR analysis of *IKZF1* Isoform 1 transcript expression. *B*: qPCR analysis of *IKZF1* Isoform 2 transcript expression. δCt were calculated using the *IKZF1* Isoform 1 or Isoform 2 qPCR Ct value minus the single copy gene β2 microglobulin (B2M) qPCR Ct value. Expression values were compared via one-way ANOVA using Prism software.](1041fig1){#F1}

DISCUSSION {#s14}
==========

We provide evidence that the minor allele of rs10272724 (C), in near-perfect LD with the minor, C-ALL--susceptible, allele of rs4132601 (G), is protective from type 1 diabetes. Of the nearby genes in the region, *IKZF1* appeared to be the most likely candidate causal gene for type 1 diabetes in this region given its causal role in C-ALL and its known role in lymphocyte development. However, our analysis revealed that the previously reported correlation of *IKZF1* mRNA expression with rs4132601 may be inaccurate given complications with the probe used in the data accessed by Papaemmanuil et al. ([@B8]). Furthermore, an *IKZF1* genotype-phenotype correlation at rs10272724 was not confirmed by our qPCR analysis of PBMCs. *IKZF1* is now an attractive candidate causal gene in type 1 diabetes, and a functional link between rs10272724 and *IKZF1* may yet be elucidated on examining specific isoforms of Ikaros. We note that our qPCR assay evaluated the expression of two transcripts conserved across 10 splice variants of *IKZF1*, spanning six of the seven identified active and dominant-negative isoforms of the protein. In addition, many allele-specific effects on gene expression are known to be tissue or cell-type specific and may even be restricted to particular phases of development. Another ALL-related gene, AF4/FMR2 family member 3 (*AFF3*), has been associated with type 1 diabetes ([@B10]) (J. Cooper, C.W., and J.A.T., unpublished observations), so our report also confirms a second genetic link between these diseases. *AFF3* has been implicated as a susceptibility allele in rheumatoid arthritis (rs10865035 and rs9653422) ([@B16]), further highlighting the connection between autoimmunity and lymphoid cancers.

Our finding with *IKZF1* marks the third Ikaros family member to be associated with type 1 diabetes, the others being the transcription factors Ailios (*IKZF3*) on chromosome 17q21.2 and Eos (*IKZF4*) on chromosome 12q13.2 ([@B10],[@B17]), whose targets include *BCL-2* and *FOXP3*, respectively. Ikaros family members interact to coordinate functions of immunologic development and homeostasis ([@B18]), so it will be important to explore the effect of these interactions in disease etiology. The more than 30 reported interaction partners of the Ikaros family members (<http://www.t1dbase.org>) suggest the role of *IKZF1* in type 1 diabetes could be subtle and yet far reaching. Interactions with the histone deacetylase and chromodomain-helicase-DNA-binding families of proteins suggest chromosome remodeling events could be involved ([@B11],[@B19]). Ikaros interactions with the Notch ([@B18]) and STAT ([@B20]) protein families also suggest that signaling events that affect T-cell activation and maturation could affect the ultimate development of a diabetogenic, leukemia-protected or nondiabetogenic, leukemia-susceptible T-cell repertoire. Thus, further investigation is warranted to elucidate the phenotypic effect of the genetic feature marked by rs10272724, its impact on *IKZF1*, and the role of Ikaros in autoimmunity.

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0446/-/DC1>.
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